You are here
Public submissions on scheduling matters referred to the ACMS #31 and Joint ACMS-ACCS #25 meetings held in June 2020
Scheduling of chemicals and poisons
Published
Public submissions made in response to:
- the delegates' proposed amendments to the Poisons Standard published on 17 April 2020 and 24 April 2020 and received before the first closing date under regulation 42ZCZK of the Therapeutic Goods Regulations 1990 (the Regulations); and
Public submissions on proposed amendments to be referred to an expert advisory committee
Public submissions on proposed amendments referred to the ACMS #31
*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open it from there.
Oxymetazoline
- Consultation submission: Australian Medical Association (AMA) (pdf,245kb)
- Consultation submission: Industry Stakeholder (pdf,40kb)
- Consultation submission: NSW Poisons Information Centre (NSW PIC) (pdf,292kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,293kb)
- Consultation submission: The Pharmacy Guild of Australia (PGA) (607kb)*
Eletriptan
- Consultation submission: Australian Medical Association (AMA) (pdf,245kb)
- Consultation submission: NSW Poisons Information Centre (NSW PIC) (pdf,292kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,293kb)
- Consultation submission: The Pharmacy Guild of Australia (PGA) (607kb)*
Clotrimazole
- Consultation submission: Australasian College of Dermatologists (pdf,324kb)
- Consultation submission: Australian Medical Association (AMA) (pdf,245kb)
- Consultation submission: NSW Poisons Information Centre (NSW PIC) (pdf,292kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,293kb)
- Consultation submission: The Pharmacy Guild of Australia (PGA) (607kb)*
Sildenafil
- Consultation submission: Australian Medical Association (AMA) (pdf,245kb)
- Industry stakeholder - The submitter did not give permission to publish their name and their submission
- Industry stakeholder - The submitter did not give permission to publish their name and their submission
- Consultation submission: NSW Poisons Information Centre (NSW PIC) (pdf,292kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,293kb)
- Consultation submission: The Pharmacy Guild of Australia (PGA) (607kb)*
- Consultation submission: The Society of Hospital Pharmacists Australia (SHPA) (pdf,670kb)*
Ibuprofen
- Consultation submission: Australian Medical Association (AMA) (pdf,245kb)
- Consultation submission: Consumer Healthcare Products Australia (CHP Australia) (pdf,160kb)
- Consultation submission: GlaxoSmithKline (GSK) (pdf,75kb)
- Consultation submission: Individual (pdf,42kb)
- Consultation submission: NSW Poisons Information Centre (NSW PIC) (pdf,292kb)
- Consultation submission: Pain Australia (pdf,213kb)
- Consultation submission: The Pharmacy Guild of Australia (PGA) (607kb)*
- Consultation submission: The Society of Hospital Pharmacists Australia (SHPA) (pdf,670kb)*
Cumyl-pegaclone
Public submissions on proposed amendments referred to the Joint ACMS-ACCS #25
Cannabidiol (private application and delegate initiate)
- Consultation submission: AIO Unlimited (pdf,771kb)*
- Consultation submission: Althea (pdf,575kb)*
- Consultation submission: Applied Cannabis Research (pdf,235kb)
- Consultation submission: Arthur Kerr (pdf,158kb)
- Consultation submission: Aurora Cannabis Enterprises (pdf,1.62Mb)*
- Consultation submission: AusCann (pdf,360kb)
- Consultation submission: Australasian College of Dermatologists (pdf,455kb)
- Consultation submission: Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (pdf,275kb)
- Consultation submission: Australian & New Zealand Society of Palliative Medicine Limited (ANZSPM) (pdf,227kb)
- Consultation submission: Australian Hemp Party and Nimbin Hemp Embassy (pdf,239kb)
- Consultation submission: Australian Industrial Hemp Alliance (pdf,374,kb)
- Consultation submission: Australian Medical Association (AMA) (pdf,247kb)
- Consultation submission: Australian Taxpayers' Alliance (ATA) (pdf,207kb)
- Consultation submission: Australian Traditional-Medicine Society (ATMS) (pdf,78kb)
- Consultation submission: BBS Pharmaceuticals (pdf,489kb)
- Consultation submission: CA Clinics (pdf,321kb)
- Consultation submission: Cancer Council Australia (pdf,295kb)
- Consultation submission: Cannabis Horticulture Australia (pdf,115kb)
- Consultation submission: CannaPacific Pty Ltd - The submitter did not give permission to publish their submission
- Consultation submission: Cannvalate (pdf,352kb)
- Consultation submission: CBD Reviews Australia (pdf,193kb)
- Consultation submission: Complementary Medicines Australia (CMA)(pdf,710kb)*
- Consultation submission: Consumer Healthcare Products Australia (CHP Australia) (pdf,174kb)
- Consultation submission: Cronos Australia (pdf,185kb) (pdf,kb)
- Consultation submission: CSIRO (pdf,272kb)
- Consultation submission: Dalgarno Institute (pdf,696kb)*
- Consultation submission: Delta Tetra (pdf,45kb)
- Consultation submission: Department of Health and Human Services Victoria (pdf,100kb)
- Consultation submission: Drug Free Australia (pdf,6.28Mb)*
- Consultation submission: Drug Free Australia QLD (pdf,38kb)
- Consultation submission: ECS Botanics (pdf,2.3Mb)*
- Consultation submission: Elixinol Global Limited (pdf,347kb)
- Consultation submission: Estelle Ross (pdf,171kb)
- Consultation submission: Faculty of Pain Medicine (FPM) of the Australian and New Zealand College of Anaesthetists (pdf,319kb)
- Consultation submission: Federation of Chinese Medicine & Acupuncture Societies of Australia Ltd. (FCMA) (pdf,317kb)
- Consultation submission: FreshLeaf Analytics (pdf,193kb)
- Consultation submission: GW Pharmaceuticals (pdf,323kb)
- Consultation submission: Health House International - The submitter did not give permission to publish their submission
- Consultation submission: Hemp Fields (pdf,254kb)
- Consultation submission: Hemp Harvests - The submitter did not give permission to publish their submission
- Consultation submission: Higher Wave Wellness (pdf,127kb)
- Consultation submission: iCannabis - The submitter did not give permission to publish their submission
- Consultation submission: Individual (pdf,32kb)
- Consultation submission: Individual (pdf,15kb)
- Consultation submission: Individual (pdf,74kb)
- Consultation submission: Individual (pdf,56kb)
- Consultation submission: Individual (pdf,13kb)
- Consultation submission: Individual (pdf,95kb)
- Consultation submission: Individual (pdf,60kb)
- Consultation submission: Individual (pdf,11kb)
- Consultation submission: Individual (pdf,213kb)
- Consultation submission: Individual (pdf,352kb)
- Consultation submission: Individual (pdf,48kb)
- Consultation submission: Individual (pdf,10kb)
- Consultation submission: Individual (pdf,21kb)
- Consultation submission: Individual (pdf,293kb)
- Consultation submission: Individual (pdf,64kb)
- Consultation submission: Individual (pdf,70kb)
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Individual - The submitter did not give permission to publish their name and their submission
- Consultation submission: Industrial Hemp Western Australia Association Inc. (pdf,110kb)
- Consultation submission: Industry stakeholder - The submitter did not give permission to publish their name and their submission
- Consultation submission: Industry stakeholder - The submitter did not give permission to publish their name and their submission
- Consultation submission: Industry stakeholder - The submitter did not give permission to publish their name and their submission
- Consultation submission: Industry stakeholder - The submitter did not give permission to publish their name and their submission
- Consultation submission: Industry stakeholder - The submitter did not give permission to publish their name and their submission
- Consultation submission: Industry stakeholder - The submitter did not give permission to publish their name and their submission
- Consultation submission: Industry stakeholder - The submitter did not give permission to publish their name and their submission
- Consultation submission: Infused Products International (pdf,202kb)
- Consultation submission: Integria Health Care (pdf,355kb)
- Consultation submission: John Nguyen (pdf,86kb)
- Consultation submission: Joshua D'Antino (pdf,355kb)
- Consultation submission: Lambert Initiative for Cannabinoid Therapeutics, University of Sydney (pdf,634kb)*
- Consultation submission: Little Green Pharma (pdf,652kb)*
- Consultation submission: Medicinal Cannabis Industry Australia (pdf,163kb)
- Consultation submission: Medicinal Organic Cannabis Australia (MOCA) (pdf,9kb)
- Consultation submission: Melissa Costin (pdf,514kb)*
- Consultation submission: Metagenics (pdf,209kb)
- Consultation submission: Multiple Sclerosis Australia, Multiple Sclerosis Research Australia (pdf,252kb)
- Consultation submission: Naturopaths and Herbalists Association of Australia (pdf,107kb)
- Consultation submission: NICM Health Research Institute, Western Sydney University (pdf,52kb)
- Consultation submission: NSP Development (pdf,137kb)
- Consultation submission: NSW Health (pdf,385kb)
- Consultation submission: NSW Industrial Hemp Association (pdf,445kb)
- Consultation submission: NSW Poisons Information Centre (pdf,210kb)
- Consultation submission: Pain Australia (pdf,3.4Mb)*
- Consultation submission: Pharmacare (pdf,148kb)
- Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,170kb)
- Consultation submission: Pharmacy Guild of Australia (pdf,171kb)
- Consultation submission: Science Party Australia (pdf,95kb)
- Consultation submission: Tasmanian Alkaloids (TasAlk) (pdf,561kb)*
- Consultation submission: Tasmanian Hemp Association (pdf,239kb)
- Consultation submission: THC Global Group Limited (pdf,544kb)*
- Consultation submission: The Royal Australian & New Zealand College of Psychiatrists (RANZCP) (pdf,102kb)
- Consultation submission: The Society of Hospital Pharmacists Australia (SHPA) (pdf,670kb)*
- Consultation submission: United in Compassion - The submitter did not give permission to publish their submission
- Consultation submission: Individual submissions made through Your Health Your Choice - Part 1 (pdf,3.80Mb)*
- Consultation submission: Individual submissions made through Your Health Your Choice - Part 2 (pdf,3.62Mb)*
- Consultation submission: Individual submissions made through Your Health Your Choice - Part 3 (pdf,3.79Mb)*
- Consultation submission: Individual submissions made through Your Health Your Choice - Part 4 (pdf,4.33Mb)*
- Consultation submission: Individual submissions made through Your Health Your Choice - Part 5 (pdf,5Mb)*
- Consultation submission: Individual submissions made through Your Health Your Choice - Part 6 (pdf,3.39Mb)*
- Consultation submission: Submission statistics provided by Your Health Your Choice (pdf,346kb)
Isothiazolinones, methylisothiazolinone and methylchloroisothiazolinone
- Consultation submission: Accord (pdf,59kb)
- Consultation submission: Australasian College of Dermatologists (pdf,324kb)
- Consultation submission: Australian Food and Grocery Council (AFGC) (pdf,209kb)
- Consultation submission: Australian Medical Association (AMA) (pdf,245kb)
- Consultation submission: Australian Paint Manufacturers' Federation Inc. (APMF) (pdf,103kb)
- Consultation submission: Australian Pesticides and Veterinary Medicines Authority (APVMA) (pdf,56kb)
- Consultation submission: Chemistry Australia (pdf,127kb)
- Consultation submission: Ego Pharmaceuticals (pdf,270kb)
- Consultation submission: Industry stakeholder - The submitter did not give permission to publish their name and their submission
- Consultation submission: Industry stakeholder - The submitter did not give permission to publish their name and their submission
- Consultation submission: Natures Organics (pdf,520kb)*
- Consultation submission: New Zealand Paint Manufacturers Association Inc. (NZPMA) (pdf,311kb)
- Consultation submission: Procter & Gamble Australia (P&am;G) (pdf,1.63Mb)*
- Consultation submission: The Pharmacy Guild of Australia (PGA) (607kb)*
- Consultation submission: Thor Specialties - The submitter did not give permission to publish their submission
Outcome of
- ACMS #31, June 2020
- Joint ACMS-ACCS meeting #25, June 2020
- Consultation: Proposed amendments to the Poisons Standard - ACMS and Joint ACMS/ACCS meetings, June 2020
- Consultation: Proposed amendments to the Poisons Standard - Joint ACMS/ACCS meetings, June 2020
- Advisory Committee on Medicines Scheduling (ACMS)
- Advisory Committee on Chemicals Scheduling (ACCS)